Fusion Pharmaceuticals Inc.
Clinical trials sponsored by Fusion Pharmaceuticals Inc., explained in plain language.
-
New Two-Pronged attack on Tough-to-Treat prostate cancer
Disease control OngoingThis study is testing a new combination treatment for men with an advanced form of prostate cancer that has spread and no longer responds to standard hormone therapy. It combines a radioactive drug that seeks out cancer cells with a pill that blocks cancer's ability to repair its…
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Targeted radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis study is testing a new targeted radiation treatment called FPI-2265 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment delivers radiation directly to cancer cells using a molecule that seeks out a protein o…
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC